Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegol-Sihematide Dose-Ranging in Non-Dialysis CKD Anemia
NCT02403362Phase 2Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2014
- Primary completion
- Oct 2015
- Modality
- PEGylated Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of peglmolesatide in anemia (3 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Percentage of participants who achieved a target hemoglobin response at Week 24. Status: unknown.
02
Drugs
peglmolesatide
03
Conditions
anemia
Beyond the preview
Go deeper on NCT02403362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02403362.